AlzeCure Pharma
30.8.2021 14:11:55 CEST | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / August 30, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that the company has received approval from the regulatory authorities in Sweden to begin the next clinical phase I study (multiple ascending dose, MAD) with the candidate drug ACD856 focused on Alzheimer's disease.
The MAD Phase I study is AlzeCure's third clinical study with ACD856, the lead candidate drug within the company's NeuroRestore platform. ACD856 is being developed as a symptom-relieving treatment for disease states where the cognitive ability is impaired, such as in Alzheimer's disease. The primary study goal is to evaluate ACD856's tolerability and safety after repeated dosing, as well as to examine early signals on brain activity.
The substances in the NeuroRestore platform stimulate several important signaling pathways in the brain, which, among other things, leads to improved cognition. Preclinical studies have shown that AlzeCure's candidate drugs strengthen the communication between nerve cells and improve cognitive ability including memory functions.
"I'm very pleased that we have all regulatory approvals in place to be able to start the next study with ACD856. This means we will be able to start the MAD study during the fall, which is in line with our previously communicated goals," said Johan Sandin, CSO at AlzeCure Pharma.
"This is a statement of strength that shows that AlzeCure continues to deliver according to plan," said Martin Jönsson, CEO of AlzeCure Pharma AB. "Diseases with cognitive disorders, and especially Alzheimer's disease, are areas with high need of new, more effective treatments and I am very much looking forward to the continued development of this important candidate drug".AlzeCure Pharma will give a strategic update on Alzheimer's disease and the NeuroRestore platform on September 1 at 9 a.m. CET at Redeye. Watch the livestream via: https://www.redeye.se/events/816325/strategy-update-alzecure-pharma-2.
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser., For more information, please visit www.alzecurepharma.se .
About NeuroRestore
NeuroRestore is a platform of symptom-relieving drug candidates for disease states in which cognitive ability is impaired, e.g. Alzheimer's Disease, sleep apnea, traumatic brain injury and Parkinson's disease. NeuroRestore stimulates several important signaling pathways in the brain, which among other things leads to improved cognition. In preclinical studies with NeuroRestore we have been able to show that our drug candidates enhance communication between the nerve cells and improve cognitive ability. NeuroRestore stimulates specific signaling pathways in the central nervous system known as neurotrophins, the most well-known being NGF (Nerve Growth Factor) and BDNF (Brain Derived Neurotrophic Factor). The levels of NGF and BDNF are disturbed in several disease states and the signaling is reduced. The impaired function impairs communication between the synapses, i.e. the contact surfaces of the nerve endings, as well as reducing the possibility of survival for the nerve cells, which gives rise to the cognitive impairments. Neurotrophins play a crucial role for the function of nerve cells, and a disturbed function of BDNF has a strong genetic link to impaired cognitive ability in several different diseases, such as Alzheimer's, Parkinson's disease, traumatic brain injury and sleep disorders. There is also a link between BDNF signaling and depression, something that has been further strengthened in recent years.
About Alzheimer's disease
Alzheimer's disease is the most common form of dementia, affecting approximately 45 million people worldwide. Alzheimer's disease is a lethal disorder that also has a large impact on both relatives and the society. Today, preventive and disease modifying treatments are missing. The main risk factors to develop Alzheimer's are age and genetic causes. Even though the disease can start as early as between 40 and 65 years of age, it is most common after 65 years. Significant investments in Alzheimer research are being made because of the significant unmet medical need and the large cost of this disease for healthcare and society. The total global costs for dementia related diseases is estimated to about 1,000 billion USD globally in 2018. Given the lack of both effective symptomatic treatments and disease modifying treatments, the need for new effective therapies is acute. The few approved drugs on the market today have only a limited symptomatic effect and can produce dose limiting side effects. A disease modifying treatment for Alzheimer's disease is estimated to reach more than $10 billion in annual sales. In Sweden, approximately 100,000 people suffer from Alzheimer's disease with a healthcare cost of about SEK 63 billion yearly, which is more than for cancer and cardiovascular diseases combined.
Image Attachments
Martin Jönsson CEO AlzeCure Pharma
Attachments
AlzeCure's Alzheimer's project receives approval to start next clinical phase I study with ACD856
SOURCE: AlzeCure Pharma
View source version on accesswire.com:
https://www.accesswire.com/661943/AlzeCures-Alzheimers-Project-Receives-Approval-to-start-Next-Clinical-Phase-I-Study-with-ACD856
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Model ML Secures Investment From HSBC Asset Management to Scale Its Agentic Operating System for Financial Services12.8.2026 18:05:00 CEST | Press release
The investment reflects growing demand for specialist AI platforms designed specifically for financial services. LONDON, UK / ACCESS Newswire / August 12, 2026 / Model ML has announced an investment from HSBC Asset Management, made through its flagship Venture Capital (VC) strategy. The funding will support Model ML's growth as the focus of enterprise AI shifts from individual models to the systems required to implement them. Model ML's platform is purpose-built for financial services. The company works with many of the world's leading banks, asset managers and advisory firms, helping to automate complex workflows across research, due diligence, financial analysis and client-ready document creation, while maintaining governance, accuracy and consistency. Its model-agnostic approach routes each task to the AI model best suited to the job, enabling firms to benefit from advances across the AI ecosystem without changing the way teams work. The company has grown rapidly since launching les
GoodData.AI Cuts BI Migration From 18 Months to Weeks for DACH Enterprises, Opening the Fastest Route to Production AI12.8.2026 16:20:00 CEST | Press release
With around 80 percent of migration functions automated, enterprises skip the multi-year consulting engagement that has kept them on aging BI platforms. SAN FRANCISCO, CA / ACCESS Newswire / August 12, 2026 / GoodData.AI today announced its AI-driven BI migration offering for enterprises across Germany, Austria, and Switzerland, delivered with German-language support and a regional team. Migration agents are able to move organizations off Tableau, Power BI, Qlik, Looker, MicroStrategy, and any other BI platform in days to weeks instead of the 12 to 18 months that a manual rebuild takes. Up to 80 percent of the migration work is automated, which cuts the cost along with the timeline, and GoodData engineers review every change before the customer approves it. It follows GoodData.AI's expansion in the region earlier this year and its work with DATEV, one of Germany's most recognized enterprise software companies. "Every migration conversation in Germany starts with the same question: will
Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America12.8.2026 15:00:00 CEST | Press release
Collaboration provides Karbon-X with an opportunity to apply its project development and carbon market capabilities to commercial transportation infrastructure in the Southern Cone. CALGARY, AB / ACCESS Newswire / August 12, 2026 / Karbon-X Corp. (OTCQB:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has signed a non-binding Letter of Intent ("LOI") with Core Energy ("Core Energy"), to explore a potential commercial electric vehicle ("EV") fast-charging infrastructure project in South America. The proposed collaboration is intended to bring together Core Energy's local project development capabilities and Karbon-X's experience evaluating and developing climate projects and carbon market opportunities. During the initial exploratory phase, the companies expect to jointly assess the project's preliminary technical and commercial considerations and prepare a Concept Note outlining the proposed infrastructure model and its pot
Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador11.8.2026 23:15:00 CEST | Press release
Doubles Fermi power to market to 4.8 gigawatts (GW) over the next ~30 months Build-Own-Operate-Transfer structure accelerates one of America's largest AI campus power programs - with no capital outlay by Fermi DALLAS, TX / ACCESS Newswire / August 11, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), announced the execution of a framework agreement with Hillcore Energy Capital Corporation ("Hillcore") under which Hillcore will finance, build, own and operate the Hillcore Power Center, an approximately 2.6 GW power complex at Fermi's Project Matador campus in Carson County, Texas, under a Build-Own-Operate-Transfer (BOOT) structure. The Hillcore Power Center will comprise approximately 2.5 GW of natural gas-fired generation, developed in phases, together with approximately 100 megawatts (MW) of solar generation and battery energy storage. Construction of the first power block, approximately 350 MW, will begin on execution of definitive ag
ePropelled to Increase Manufacturing Footprint with $60 Million in U.S. Government Funding to Strengthen U.S. Drone Propulsion Supply Chain11.8.2026 13:00:00 CEST | Press release
Expansion Increases Manufacturing Capacity by 4X and Positions ePropelled as a Leading Domestic Supplier of Advanced Dual-Use Electric Propulsion Systems COVENTRY, UK / ACCESS Newswire / August 11, 2026 / ePropelled, a leading U.S. manufacturer of advanced electric propulsion systems for uncrewed aerial vehicles, aerospace, defense, and commercial applications, today announced a major expansion of its manufacturing operations, increasing its production footprint from 20,000 square feet to 80,000 square feet. The expansion is supported by $60 million in government funding through the Department of War's Industrial Base Analysis and Sustainment program, reinforcing the nation's commitment to strengthening domestic manufacturing of mission-critical drone technologies and advanced dual-use propulsion systems. The expanded facility will increase ePropelled's propulsion system production capacity by more than 4X, enabling the company to meet rapidly growing demand from U.S. government progra
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom